Denkert, Carsten
Lebeau, Annette
Schildhaus, Hans Ulrich
Jackisch, Christian
Rüschoff, Josef
Funding for this research was provided by:
Philipps-Universität Marburg
Article History
Accepted: 1 September 2022
First Online: 13 October 2022
Einhaltung ethischer Richtlinien
:
: C. Denkert gibt an: AstraZeneca (Consulting Fees [e.g., advisory boards]); Daiichi Sankyo (Consulting Fees [e.g., advisory boards]); Lilly (Consulting Fees [e.g., advisory boards]); Molecular Health (Consulting Fees [e.g., advisory boards]); MSD Oncology (Consulting Fees [e.g., advisory boards]); Roche (Consulting Fees [e.g., advisory boards]); Sividon Diagnostics (Ownership Interest [stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds]); VMScope (Receipt of Intellectual Property Rights/Patent Holder, Royalty). A. Lebeau gibt an: AstraZeneca (Consulting und Lecure Fees); Daiichi Sankyo (Consulting und Lecture Fees); MSD Sharp@Dhome (Consulting und Lecture Fees); Roche Pharma AG (Consulting und Lecture Fees; Study Support); Myriad Genetics (Lecture Fees); Novartis (Consulting und Lecture Fees); Diaceutics (Consulting Fees); QuIP GmbH (Consulting Fees). H. U. Schildhaus gibt an: MSD, BMS, Roche Pharma, Novartis Oncology, AstraZeneca, Eisai, Takeda, ZytoVision, Zytomed Systems, Molecular Health (Honorare einschl. Advisory Boards). C. Jackisch gibt an: AstraZeneca (Consulting Fees [e.g., advisory boards]); Daiichi Sankyo (Consulting Fees [e.g., advisory boards]); ExactSciences (Consulting Fees [e.g., advisory boards]); Lilly (Consulting Fees [e.g., advisory boards]); Molecular Health (Consulting Fees [e.g., advisory boards]); Novartis (Consulting Fees [e.g., advisory boards]); Lilly (Consulting Fees [e.g., advisory boards]); Pierré-Fabre (Consulting Fees [e.g., advisory boards]); MSD Oncology (Consulting Fees [e.g., advisory boards]); Roche (Consulting Fees [e.g., advisory boards]). J. Rüschoff gibt an: Scientific Advisory Boards und Presentations: Astra-Zeneca, BMS, Daiichi Sankyo, GSK, MSD/Merck und Roche. Co-Founder Targos Molecular Pathology GmbH (Kassel/Germany).
: Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.